Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Roche Innovation Center Basel, F. Hofman La Roche, Basel, Switzerland.
Cancer Genomics Proteomics. 2019 Mar-Apr;16(2):99-119. doi: 10.21873/cgp.20116.
The death toll of non-small cell lung cancer (NSCLC) patients is primarily due to metastases, which are poorly amenable to therapeutic intervention. In this review we focus on miRs associated with metastasis of NSCLC as potential new targets for anti-metastatic therapy. We discuss miRs validated as therapeutic targets by in vitro data, identification of target(s) and pathway(s) and in vivo efficacy data in at least one clinically-relevant metastasis-related model. A few of the discussed miRs correlate with the clinical status of NSCLC patients. Using miRs as therapeutic agents has the advantage that targeting a single miR can potentially interfere with several metastatic pathways. Depending on their mode of action, the corresponding miRs can be up- or down-regulated compared to normal matching tissues. Here, we describe therapeutic approaches for reconstitution therapy and miR inhibition, general principles of anti-metastatic therapy as well as current technical pitfalls.
非小细胞肺癌（NSCLC）患者的死亡率主要归因于转移，而转移对治疗干预的反应较差。在这篇综述中，我们重点讨论了与 NSCLC 转移相关的 miRs，它们可能成为抗转移治疗的新靶点。我们讨论了通过体外数据、靶标和途径的鉴定以及至少一种临床相关转移相关模型中的体内疗效数据验证的作为治疗靶点的 miRs。讨论的一些 miRs 与 NSCLC 患者的临床状况相关。使用 miRs 作为治疗剂的优点在于靶向单个 miR 可能潜在地干扰几个转移途径。根据其作用模式，相应的 miRs 可以与正常匹配组织相比上调或下调。在这里，我们描述了再构成治疗和 miR 抑制的治疗方法、抗转移治疗的一般原则以及当前的技术难点。
